e.g. mhealth
Search Results (1 to 6 of 6 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 4 JMIR Research Protocols
- 1 JMIR Formative Research
- 1 JMIR Medical Informatics
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
This sentiment analysis focuses on Twitter discussions about ivermectin, showing public opinion that, while not devoid of misinformation risks, these discussions offer an alternative lens to understand the societal pulse on this contentious topic [6]. By examining the sentiments expressed on Twitter, we aim to add nuance to the ongoing discourse, acknowledging the platform's influence on public perception and its implications for health communication strategies.
JMIR Form Res 2025;9:e50536
Download Citation: END BibTex RIS
Primary objective is to assess the impact of a combined approach of repeated ivermectin MDA and SMC on malaria incidence in children aged ≤10 years (active case detection [ACD] cohort; assessed weekly), with the purpose of testing the superiority of ivermectin compared with placebo for reducing malaria incidence.
JMIR Res Protoc 2023;12:e41197
Download Citation: END BibTex RIS
Combining an antimalarial treatment (DP) with an endectocide treatment able to reduce vector survival, ivermectin (IVM), could increase the impact of MDA and offer a new tool to reduce malaria transmission [15,16]. IVM is a broad-spectrum antiparasitic endectocidal drug, active against a wide range of parasites, including ectoparasites [17].
JMIR Res Protoc 2020;9(11):e20904
Download Citation: END BibTex RIS
Ivermectin is an effective drug against pneumonia and diarrhea, and has recently been claimed to successfully treat patients with COVID-19 as well [56]. It is a US Food and Drug Administration (FDA)–approved drug used for parasitic infections, which has the potential to be repurposed. Ivermectin inhibits the replication of SARS-Co V-2 in vitro [57]. Recently, a team of medical doctors in Bangladesh reported quick recoveries of patients with COVID-19 using this drug [58].
JMIR Med Inform 2020;8(11):e21648
Download Citation: END BibTex RIS
In 2015, after more than 15 years of administering ivermectin annually, nearly all epilepsy cases were in people over the age of 20 years, also suggesting a protective effect of ivermectin on the incidence of epilepsy (R Colebunders, personal communication). A similar age shift of epilepsy cases to older age groups after the introduction of ivermectin was reported in an onchocerciasis-endemic region in Nigeria [14].
JMIR Res Protoc 2017;6(8):e137
Download Citation: END BibTex RIS
Three in vivo studies assessed the long-term effect of ivermectin on mosquito survival by conducting feedings at least 7 days after administration of ivermectin [10,13,14].
JMIR Res Protoc 2016;5(4):e213
Download Citation: END BibTex RIS